Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
Neurocrine(NBIX) stock is priced at $159.82, giving the company a market capitalization of 16.24B. It carries a P/E multiple of 24.35.
As of 2026-08-07, Neurocrine(NBIX) stock has fluctuated between $158.48 and $162.51. The current price stands at $159.82, placing the stock +0.8% above today's low and -1.7% off the high.
Neurocrine(NBIX) shares are trading with a volume of 1.3M, against a daily average of 1.67M.
During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.
During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.
NBIX News
Wedbush raised the firm’s price target on Neurocrine (NBIX) to $194 from $185 and keeps an Outperform rating on the shares. The Q2 quarterly report reflected st...
...
Neurocrine Biosciences (NBIX) is back in focus after reporting strong second quarter 2026 results, lifting full year INGREZZA sales guidance, and outlining high...
Analyst ratings
87%
of 31 ratingsMore NBIX News
Neurocrine Biosciences ((NBIX)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing too...
In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, with earnings per share rising ye...
Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.86. In...
Wells Fargo thinks Neurocrine (NBIX) stock’s weakness today despite a “solid beat and raise quarter” last night is “overdone.” Fundamentals improved on EPS and...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.